Dental Literature Watch · Trial · Periodontics
Timing of Metronidazole + Amoxicillin in Perio Therapy Does Not Change the Outcome
TL;DR
- The long-standing teaching is that systemic antibiotics must be timed to the completion of debridement so the biofilm is disrupted when the drug arrives.
- This trial tested that directly: metronidazole plus amoxicillin during a 14-day course of scaling and root planing, versus immediately after it.
- Clinical outcomes were the same. About 60% of each group reached the endpoint of no more than four sites with probing depth ≥ 5 mm at one year.
- No significant difference in probing depth or attachment level reduction.
- The early group showed faster microbiological change, which did not translate into a clinical advantage.
The study
| Design | Double-blind, placebo-controlled randomised clinical trial |
| Population | 68 subjects with stage III/IV periodontitis, 34 per group |
| Early arm | Metronidazole + amoxicillin three times daily during 14 days of SRP, then placebo |
| Late arm | Placebo during SRP, then metronidazole + amoxicillin immediately after |
| Primary endpoint | ≤ 4 sites with PD ≥ 5 mm at 1 year — reached by ~60% in each group (p > 0.05) |
| Microbiology | Checkerboard DNA-DNA hybridisation, 40 species, 9 sites per subject; early arm changed faster |
💎 Insight — what this means chairside
It buys you scheduling freedom, not a new protocol
If a patient needs several quadrants over a fortnight, you no longer have to choreograph the prescription around the final appointment.
That is a genuine practical gain in a busy list, even though nothing about the indication changes.
If a patient needs several quadrants over a fortnight, you no longer have to choreograph the prescription around the final appointment.
That is a genuine practical gain in a busy list, even though nothing about the indication changes.
The microbiology moved and the patient did not
The early group cleared pathogens faster without doing better clinically at a year.
This is a useful reminder that subgingival species counts are a mechanism, not an outcome.
The early group cleared pathogens faster without doing better clinically at a year.
This is a useful reminder that subgingival species counts are a mechanism, not an outcome.
Notice what this trial does not question
Both arms received systemic antibiotics. This is a trial about when, not whether.
The larger question of which stage III/IV patients actually need metronidazole and amoxicillin at all sits outside it.
Both arms received systemic antibiotics. This is a trial about when, not whether.
The larger question of which stage III/IV patients actually need metronidazole and amoxicillin at all sits outside it.
⚠️ The catch
Sixty-eight patients
With 34 per arm and a roughly 60% endpoint rate in both, this trial can exclude a large difference but not a modest one.
Read it as "timing does not appear to matter much", not as proven equivalence.
With 34 per arm and a roughly 60% endpoint rate in both, this trial can exclude a large difference but not a modest one.
Read it as "timing does not appear to matter much", not as proven equivalence.
Antibiotic stewardship is the elephant
Adjunctive systemic antibiotics in periodontitis remain contested, and current European guidance restricts them to selected cases rather than routine use.
A trial optimising the timing of a debated intervention does not settle whether to give it.
Adjunctive systemic antibiotics in periodontitis remain contested, and current European guidance restricts them to selected cases rather than routine use.
A trial optimising the timing of a debated intervention does not settle whether to give it.
⚡ Bottom line
- Staging SRP over two weeks and wondering when to prescribe → either during or immediately after; outcomes were the same at a year.
- Choosing whether to prescribe at all → this trial does not help. Both arms got antibiotics.
- Tempted by the faster microbiological clearance → it did not produce a better clinical result.
🧪 Questions
Tap an answer — instant grade, deciding line, and the trap.
You are treating a 52-year-old with stage III periodontitis and have planned full-mouth scaling and root planing across three appointments over two weeks. You have decided, with the patient, that adjunctive metronidazole and amoxicillin are indicated. Your assistant asks whether the prescription should start now or wait until the final appointment. Based on the 2026 trial, what is the best answer?
Deciding line: the trial randomised exactly this question and found about 60% of each arm reached the one-year endpoint, with no significant difference in probing depth or attachment level. Trap: the third option is the engineered trap because it correctly recalls that the early arm cleared pathogens faster and then wrongly assumes that translated into clinical benefit, which is precisely what the trial disproved; the split-course option is invented and was not tested.